e-Lung CT Biomarker Stratifies Patients at Risk of IPF Progression in a 52-Week Clinical Trial.

Anand DevarajFinja OttinkChristian Rennison-JonesFrancois-Xavier BleOlivier JolyAdnan AzimStephen GerryGeorge HarstonKristoffer OstridgePeter M George

Published in: American journal of respiratory and critical care medicine (2024)

Keyphrases

clinical trial
idiopathic pulmonary fibrosis
image quality
dual energy
computed tomography
contrast enhanced
double blind
phase ii
placebo controlled
open label
study protocol
positron emission tomography
phase iii
randomized controlled trial
magnetic resonance